HealthTell Inc Selected for iCarbonX Digital Life Alliance





HealthTell announced it has joined the Digital Life Alliance, an unprecedented ecosystem of leading bio, health networking, sequencing and artificial intelligence technology companies. The Digital Life Alliance was established byiCarbonX CEO and founder Jun Wang.

The aim of the Digital Life Alliance is to merge genetic, biological and patient-generated data with sequencing and artificial intelligence technology to rapidly detect meaningful signals about health, disease and aging, and deliver a personalized health guide for every individual. Other participating companies include PatientsLikeMe, SomaLogic, AOBiome, GALT, Imagu and Robustnique.

HealthTell’s proprietary ImmunoSignature™ Technology will contribute to the alliance by providing valuable information about how an individual’s immune system reacts to various medical, behavioral, or environmental factors. “iCarbonX has put together an impressive ecosystem of technologies and scientists to tackle this grand challenge,” said Bill Colston, CEO, HealthTell. “We are excited to be part of this unique collaboration that will lead to more cost-effective development of new health innovations and disease management strategies. We are also very pleased to have iCarbonX as an investor in HealthTell.”
Since inception HealthTell has built a powerful, reproducible, and scalable platform to deeply query the antibody complement in an individual’s blood with a wide variety of applications. HealthTell has worked with top pharmaceutical companies and clinical researchers over the past few years to help identify and characterize drug targets and leads, predict and evaluate drug response, and measure the presence or absence of disease.
About HealthTell, Inc.
Founded in 2012, HealthTell is committed to empowering the next generation of medical tests and treatments for cancer, neurological diseases, autoimmune disorders, and infectious diseases. We form strategic partnerships with diagnostic and therapeutic companies and allow them access to our proprietary ImmunoSignature platform. As the first and only platform capable of broadly characterizing antibody response, we work with these partners to uncover new biological insights that can be used to dramatically improve healthcare. For more information, please visit: http://www.healthtell.com/
Contact:
Bob Barrett
HealthTell, Inc.
(925) 361-3105